Product Alias

MHC, MY-ESO-1, CT6.1, LAGE-2, CTAG1, CTAG1B, ESO1CTAG, LAGE2A, NY-ESO-1

Species

Human

Expression sequence

Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and SLLMWITQC peptide

Accession

A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQC

Label

C-His-Avi

Expression system

HEK293

Molecular weight

The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.

Purity

> 95% as determined by SDS-PAGE and HPLC.

Endotoxin

< 1.0 EU per μg by the LAL method.

preparation

Lyophilized from 0.22 μm filtered solution in 20mM PB, 500mM NaCl (pH 7.4). Normally 8% mannitol is added as protectant before lyophilization.

Appearance

Lyophilized Powder

Biological Activity

【ELISA Data】Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&NY-ESO-1(SLLMWITQC) Antibody, hFc Tag with the EC50 of 2.3ng/ml determined by ELISA . 【SPR Data】Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag captured on CM5 Chip via Protein A can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His Tag with an affinity constant of 0.09 nM as determined in SPR assay

Reconstitution method

Centrifuge before opening the lid. Reconstitute the lyophilized protein with distilled water to a concentration of more than 100 μg/mL. It is recommended to aliquot the protein into the amount required for each experiment when using it for the first time to avoid repeated freezing and thawing.